Wednesday, November 08, 2017

How tech is making life easier for differently abled ---Whether it's apps that read restaurant bills or shoes that navigate streets, tech is giving people with special needs a shot at a better life


Scattered on technology specialist Amit Bagwe's desk beside his laptop are a Sam sung tablet and an iPhone7.
It's like any other tech worker's desk, except for the portable electronic magnifier he uses to read what's on his screen. Bagwe, who was born with low vision and lost sight in his right eye in 2005 following an accident in the chemistry lab, works with BarrierBreak in Mumbai, helping companies modify their software to include the needs of people with disabilities as well as train the disabled to use software. “Saying technology is a boon may seem like a cliché but just ask a person with a disability,“ he says.
Forced to drop out of college after the accident, the turning point came in 2012 when he signed up for a threemonth internship at BarrierBreak.“That's when I started using screen readers,“ he says. He returned to college for a BSc in information technology . “I could study on my own, navigate the city , go to a restaurant for a meal. I never thought I'd own a smartphone let alone use one,“ he says.
Assistive technology designed to help people with disabilities with their daily tasks is a huge and untapped market in India largely because developers and companies are unaware of their needs. There's been progress in recent years -for instance, buried in the settings of any smartphone are accessibility controls for the disabled -but not all products, apps and devices are easy to use since the needs of the disabled aren't considered at the design and conceptualisation stage.
Dr Nirmita Narasimhan, senior fellow and programme director, Global Initiative for Inclusive ICT, is confident that technology will reduce inequality and inability, and negate frustration. But there are hurdles. “We have screen readers but the technology is not enabled to support a third-party device, or someone hires a consultant to make a website accessible once, then more content is uploaded later and that's not accessible,“ she says.
Gaurav Mittal, co-founder of EyeD, an app that uses the smartphone's camera to guide people, says the main challenge is empathy . “Observing the world as a person who cannot see is hard. And they are slow to share deeply with us. What makes them laugh, what makes them cry, we need to know this to truly design a product that will help.“
With the app and its text reading function, a visually impaired user can navigate streets, find landmarks, and identify objects of interest. His team has also developed a customisable Eye-D keypad that makes smartphones easier to use for the blind. Mittal started Eye-D as “a hobby project“ in 2012 after spending a day at National Association for the Blind in Bengaluru during a CSR event for his former employer.“I was amazed that visually impaired people could code and use computers easily but struggled to use a smartphone and do things such as navigate the city independently,“ he says. In 2015, he quit his job and went fulltime; the app is now used by people in 160 countries. EyeD launched a Hindi reading OCR (optical character recognition) version last month, costing Rs 800.
Ajit Narayanan points out that software developed for the disabled community can serve a wider population. His Avaz app and its complementary FreeSpeech app -developed to help children with cerebral palsy, autism and speech impairment use pictures to communicate and learn grammar and language -is now also used by students in China to learn English. “Conversely, the iPad, invented for people without disabilities, had so many features that made it easy for the disabled to use,“ says Narayanan, 36. He started his company , Invention Labs, in 2007 but struggled initially to create a device.“Once the iPad was released in 2010, things took off as we could just focus on the software,“ he says. Apple's Siri and Amazon's Alexa are based on speech recognition software devel oped for the blind but are now used widely just to make life easier for everyone. Microsoft recently released a free iPhone app that uses Artificial Intelligence (AI) to tell the blind what is around them. If the phone is pointed at a park, the camera app, named Seeing AI, can describe what the scene looks like. Similarly , it can tell the amount of your restaurant bill.
The problem is that most people with disabilities are introduced to technology only at college level.“They lose so much time,“ says Siddhant Chothe, co-founder, Tekvision, a Pune-based startup that helps companies comply with accessibility standards. Chothe, who has had low vision since birth, says he's getting more enquiries for training and compliance since the government passed the Rights of Persons with Disabilities Act, 2016, which makes it mandatory for government and private service providers to make all services inclusive and accessible.Legislation means more developers will learn to create inclusive products and clients will demand them.“Inclusivity doesn't have to be an expensive afterthought,“ he says.“It's really quite simple to design keeping our needs in mind.“
In India, however, only a few can afford this technology. “This is because we are still retrofitting. All the solutions are coming from the West.We need more indigenous development,“ says Shilpi Kapoor, founder and CEO, BarrierBreak, an accessibility consulting and assistive technology firm. She's also started Newz Hook, an inclusive news website.
Dr Shamnad Basheer, founder of Increasing Diversity by Increasing Access, says the idea of disability will change over time. “With the development of AI, augmented reality, ideas like the bionic eye and other technology, the notion of disability could disappear,“ says Basheer, whose organisation has helped 23 disabled students enter law college.


Source: THE TIMES OF INDIA-7th November

Build your own cloud solution with these storage devices

These platform-agnostic network-attached storage (NAS) devices can work with almost any gadget you connect to your wireless network at office or home

WD My Cloud Personal
WD has achieved a considerable success with its consumerfriendly My Cloud products and can be accessed via mobile apps for iOS and Android. Labelled as a ‘personal cloud’, it’s a NAS box by any other measure and starts at 2TB of storage (you can also get it in 3 or 4TB).
Capacity: 2TB, 3TB or 4TB
Interface: USB 3.0, Gigabit Ethernet
Features: Remote file access, DLNA, iTunes Server.
Seagate Personal Cloud 2-Bay
Picking up on the ‘personal cloud’ theme, this unit from Seagate takes its lead from My Cloud, but it offers far larger capacities. The Seagate Personal Cloud 2-Bay NAS device can mirror the files on one hard drive to a second one, giving you protection in case one of those drives fails.
Capacity: 4TB, 6TB or 8TB
Interface: Gigabit Ethernet
Features: Remote file access, media server software, RAID support.
NAP TS-251A
The QNAP TS-251A is a great NAS device that comes with many features. It has got dual Ethernet ports, a HDMI out for connecting it up to a TV and beefy hardware including a dual-core 1.6GHz Intel Celeron CPU and 4 GB of RAM (that can be expanded to 8 GB) for hardware transcoding media files. You’ll need to buy the hard drives separately.
Features: Dual bay, WebAccess apps, Apple Time Machine support. Capacity: NA
Interface: 2 x Gigabit Ethernet, USB 3.0
Features: Remote file access, HDMI out, 4K media transcoding, DLNA.
Buffalo LinkStation LS220D
The key selling point of the 2TB dualbay NAS (it’s also available in 4, 6, and 8 TB capacities) model is that it can integrate directly with BitTorrent, meaning it can download stuff for you even when your PC is turned off. You can also stream to it via various devices.
Capacity: 2TB, 4TB, 6TB, 8TB
Interface: Gigabit Ethernet, USB 2.0
Features: Dual bay, WebAccess apps, Apple Time Machine support.
Synology DiskStation DS416+
If you want a flexible and featurerich NAS that performs well, then the Synology DiskStation DS416+ is definitely worth considering. It comes with four bays, each able to hold hard drives with capacities up to 10 TB for a combined total of 40 TB of storage space.
Capacity: Up to 40TB |
Interface: 2 x Gigabit Et her net , USB 3.0, eSATA |
Features: Quad bay, can be expanded, wake on LAN.
Western Digital DL4100
One of the coolest features of the DL4100 is its web dashboard that offers options for backing up to cloud services such as Dropbox and Box. It comes with four drive bays in your choice of four configurations. It has a 1.7GHz dual-core Atom processor and 2GB of RAM (configurable up to 6GB).
Capacity: 8TB, 16TB, 24TB
Interface: 2x Gigabit Ethernet, 2x USB 3.0, USB 2.0
Features: Dual LAN, 2GB RAM (expandable up to 6GB), NTP Client.
Apple AirPort Time Capsule
While the Time Capsule offers a seamless option for Mac users, its 2 and 3 TB storage options are expensive compared to other alternatives. As with many of the other devices here, you can use the USB port on the rear to share a USB printer or external hard drive.
Capacity: 2TB, 3TB
Interface: 3x Gigabit Ethernet, USB 2.0
Features: Automatic wireless backup, easy setup, printer and hard drive sharing.

Source:THE TIMES OF INDIA-5th November,2017


Drug firms may face U.S. probe - Dr. Reddy’s, Zydus too alleged to have violated antitrust laws, inflated prices

Twelve pharmaceutical firms, including Dr. Reddy’s Laboratories, Glenmark, Sun Pharma and Zydus, are likely to face a probe in an alleged generic drug price-fixing conspiracy in the U.S.
This was evident from a statement the Office of the Attorney General of Washington State issued on Wednesday. “A wide-ranging antitrust investigation by Attorney General Bob Ferguson and 45 other attorneys general has uncovered even more involvement in an alleged generic drug price-fixing conspiracy,” it said.
‘Expand plaint’
The States have asked a federal court to expand their pending complaint, increasing the number of drug companies from six to 18, and the number of affected drugs from two to 15. Several States in the U.S. are “alleging that the companies violated antitrust laws to artificially inflate the prices of the drugs and agreed to divvy up the market for the drugs to reduce competition. Some of the drugs increased in price by more than 1,000 %.”
Revealing this, Mr. Ferguson said: “I hold powerful interests accountable when they don’t play by the rules. That includes drug companies that conspire to fix prices, costing potentially thousands of Washingtonians in need of medication.”
The request to file an amended complaint was filed in U.S. District Court for the Eastern District of Pennsylvania, he said.
Previously, the suit named generic drug manufacturers Heritage Pharmaceuticals, Inc.; Aurobindo Pharma USA, Inc.; Citron Pharma, LLC; Mayne Pharma (USA), Inc.; Mylan Pharmaceuticals, Inc.; and Teva Pharmaceuticals USA, Inc., as defendants. The States are seeking to expand the complaint to include Actavis Holdco U.S., Inc.; Actavis Pharma, Inc.; Ascend Laboratories, LLC; Apotex Corp.; Dr. Reddy’s Laboratories, Inc.; Emcure Pharmaceuticals, Ltd.; Glenmark Pharmaceuticals, Inc.; Lannett Company, Inc.; Par Pharmaceutical Companies, Inc.; Sandoz, Inc.; Sun Pharmaceutical Industries, Inc.; and Zydus Pharmaceuticals (USA), Inc.
The original complaint, filed on December 14, 2016, alleged that the companies entered into illegal conspiracies to unreasonably restrain trade, artificially inflate and manipulate prices and reduce competition in the U.S. for two drugs — doxycycline hyclate delayed release antibiotic and glyburide oral diabetes medication.
Mr. Ferguson said generic drugs, which enter the market after a name-brand drug manufacturer loses its exclusive patent rights, offer the prospect of lower prices and greater access to prescriptions for U.S. consumers. For drugs that attract a large number of generic manufacturers, competition between them can decrease the average price by 80% or more, compared to brand-name alternatives.
In 2015, generic drug sales in the U.S. were estimated at $74.5 billion and the generic pharmaceutical industry accounts for approximately 88% of all prescriptions written in the United States.
A spokesperson of Dr. Reddy’s said the company is “aware of the on-going investigation by the U.S. Department of Justice (DoJ) into this matter and the recent amended complaint issued by the Attorneys General of Connecticut and other States. The company intends to continue cooperating fully with all authorities on this matter. As it is sub-judice, [we] wish to refrain from further comment at this point in time.”


Source: THE HINDU-3rd November,2017

Small molecule reverses antibiotic resistance - The molecule was able to enhance the activity of specific antibiotics


Using a small molecule screened from a synthetic library of 8,000 molecules, researchers at the Indian Institute of Technology (IIT) Roorkee have been able to reverse drug resistance and restore the efficacy of fluoroquinolone-group of antibiotics by inhibiting the proton gradient which drives the efflux pump. Antibiotic-resistant bacteria use the efflux pumps to expel antibiotics from the intracellular environment thus preventing antibiotics from reaching the target thus helping the bacteria to survive.
By inhibiting the proton gradient using the small molecule, the team led by Prof. Ranjana Pathania from the Department of Biotechnology at IIT Roorkee was able to inactivate the efflux, leading to an effective build-up of antibiotic inside the bacteria and subsequent bacterial death. The results were published in the International Journal of Antimicrobial Agents.
The team studied the efficiency of the small molecule in multidrug-resistant bacteria Acinetobacter baumannii. While the small molecule did not inhibit the growth of the bacteria per se, it was able to enhance the activity of a few antibiotics such as ciprofloxacin and norfloxacin in fluoroquinolone-resistant clinical isolates of A. baumannii. A. baumannii causes pneumonia, meningitis and urinary tract infections and is one of the most prevalent hospital-acquired infections across the world.
ESKAPE pathogen
“The reason for using small molecule to target A. baumannii is because it is among the six ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) that cause the most hospital-acquired infections,” says Atin Sharma from the Department of Biotechnology at IIT Roorkee and one first author of the paper.
“Since discovering new antibiotics takes a long time, boosting the activity of existing antibiotics by inhibiting the mechanism that prevents the drugs from acting will be a viable alternative,” Sharma says.
“Since the molecule inhibits the proton gradient, it and can potentially inhibit a wide variety of proton-driven efflux pumps in many multidrug-resistant pathogens,” says Prof. Pathania.
They found that lower dosage of antibiotics were sufficient to kill the bacteria when used along with the small molecule. In the case of clinical isolates of A. baumannii, when 25 micromolar of the inhibitor was used along with the antibiotic, there was a 64-fold reduction in the minimum inhibitory concentration (MIC) (the lowest concentration of the compound required to inhibit the visible growth of a pathogen) of both ciprofloxacin and norfloxacin.
“The use of small molecule inhibitor not only restores the efficacy of antibiotics but also decreases the frequency of resistant bacteria,” she says. Ciprofloxacin in combination with 50 micromolar of the inhibitor exhibited “significantly lower” mutation selection frequency compared with ciprofloxacin used alone at the same concentration.
The molecule appears safe to mammalian cells at minimum effective concentration of 16 micromolar and 32 micromolar for ciprofloxacin and norfloxacin respectively. The IC50 (a measure of toxicity) of the small molecule for human embryonic kidney cells is about 133 micromolar, which is about ten times more than the effective concentration.
“Most of the PMF [proton-motive force] inhibitors are associated with high toxicity. But the small molecule is not an inhibitor of PMF as it targets only the proton gradient and hence is not toxic to mammalian cells,” says Prof. Pathania.
The molecule has also been tested in mice models for safety and efficacy. “We could revive the activity of ciprofloxacin and norfloxacin on mice model of A. baumannii,” she says.


Source: THE HINDU-5th November,2017

Thursday, November 02, 2017

One of the activities that make us healthier, smarter and more empathic is reading. The benefits are plenty, which is especially important in a distracted, smartphone age in many people don’t learn to read. This not only endangers them socially and intellectually, but cognitively handicaps them for life, writes Derek Beres, author of Whole Motion: Training Your Brain and Body For Optimal Health, in “BigThink”.

Source | Financial Chronicle | 30th October 2017